Q-omics provides the consensus-scored ZNF887P profile across patient tissues and cancer cell-line models. ZNF887P expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF887P is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, ZNF887P RNA expression shows 23,010 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where ZNF887P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF887P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF887P survival associations across molecular data types. ZNF887P RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF887P RNA expression–survival associations across cancer types. High ZNF887P expression shows unfavorable associations in MESO, ACC, KICH, KIRP and LGG, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF887P RNA expression.
This table summarizes ZNF887P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF887P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF887P shows lower tumor expression in KIRC and higher tumor expression in LUAD, STAD, BLCA, HNSC and LUSC. The KIRC box plot shows higher ZNF887P RNA expression in normal versus tumor tissue (log2 FC = −0.394, t-test p < 0.001).
This table shows molecular features associated with ZNF887P in patient tissues and cancer cell lines. In patient samples, ZNF887P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
